These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19148468)

  • 1. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
    Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
    Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
    Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.
    Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2009 Aug; 35(2):239-48. PubMed ID: 19578736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.
    Nakamura K; Takamoto N; Hongo A; Kodama J; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
    Oncol Rep; 2008 May; 19(5):1085-91. PubMed ID: 18425362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines.
    Nakamura K; Nasu Y; Hongo A; Matsuo T; Kodama J; Ebara S; Nagai A; Abrzua F; Kumon H; Hiramatsu Y
    Int J Oncol; 2006 Feb; 28(2):393-8. PubMed ID: 16391794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
    Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
    Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
    Kauppinen JM; Kosma VM; Soini Y; Sironen R; Nissinen M; Nykopp TK; Kärjä V; Eskelinen M; Kataja V; Mannermaa A
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2133-42. PubMed ID: 20716618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
    Ponnusamy MP; Venkatraman G; Singh AP; Chauhan SC; Johansson SL; Jain M; Smith L; Davis JS; Remmenga SW; Batra SK
    Cancer Lett; 2007 Jun; 251(2):247-57. PubMed ID: 17210225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matriptase and clinical outcome of human endometrial cancer.
    Nakamura K; Hongo A; Kodama J; Abarzua F; Nasu Y; Kumon H; Hiramatsu Y
    Anticancer Res; 2009 May; 29(5):1685-90. PubMed ID: 19443387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.
    Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
    Ann Oncol; 2009 Jan; 20(1):63-70. PubMed ID: 18689863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological role and prognostic significance of NAC1 in ovarian cancer.
    Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.
    Hu C; Jiang N; Wang G; Zheng J; Yang W; Yang J
    J BUON; 2014; 19(1):215-20. PubMed ID: 24659667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness.
    Baba T; Kawaguchi M; Fukushima T; Sato Y; Orikawa H; Yorita K; Tanaka H; Lin CY; Sakoda S; Kataoka H
    J Pathol; 2012 Oct; 228(2):181-92. PubMed ID: 22262311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.
    Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2010 Sep; 37(3):605-14. PubMed ID: 20664929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
    Köbel M; Gradhand E; Zeng K; Schmitt WD; Kriese K; Lantzsch T; Wolters M; Dittmer J; Strauss HG; Thomssen C; Hauptmann S
    Int J Gynecol Pathol; 2006 Apr; 25(2):121-30. PubMed ID: 16633060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
    Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
    Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer.
    Yasuda K; Komiya A; Watanabe A; Morii A; Oya T; Nagakawa O; Fujiuchi Y; Fuse H
    Anticancer Res; 2013 Feb; 33(2):575-81. PubMed ID: 23393351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.